numerous codes of conduct set up to prevent such switching, most notably the widely respected CONSORT guidelines, which require reporting of all pre-specified outcomes and an explanation for any changes. Almost all major medical journals supposedly endorse these guidelines, and yet we know that undisclosed outcome-switching persists.
Our group has taken a new approach to trying to fix this problem. Since last October, we have been checking the outcomes reported in every trial published in five top medical journals against the prespecified outcomes from the registry entries or protocols. Most had discrepancies, many of them major. Then, crucially, we have submitted a correction letter, on every trial that misreported its outcomes, to the journal in question. (All of our raw data, methods and correspondence with journals are available on our website at COMPare-trials.org.) We expected that journals would take these discrepancies seriously, because trial results are used by physicians, researchers and patients to make informed decisions about treatments. Instead, we have seen a wide range of reactions. Some have demonstrated best practice: the BMJ, for instance, quickly published a correction on one misreported trial we found, within days of our letter being posted.
Other journals have not followed the BMJ's lead. The editors at Annals of Internal Medicine, for example, have responded to our correction letters with an unsigned rebuttal that, in our view, raises serious questions about their commitment to managing outcome-switching. For example, they repeatedly (but confusedly) argue that it is acceptable to identify "prespecified outcomes" from documents produced after a trial began; they make concerning comments that undermine the crucial resource of trial registers; and they say that their expertise allows them to permit -and even solicit -undeclared outcome-switching. Furthermore, they have declined to publish our response to their 850-word letter in the journal.
In our view, this is troubling. Annals' response helps to explain why studies repeatedly find outcome-switching to be hugely prevalent, despite policies to prevent it. But journal editors now need to engage in a serious public discussion on why this is still happening. We are providing specific worked examples to facilitate this discussion, and if our project is regarded as provocative, then that is misguided. Audit and accountability are the bread and butter of good medicine, and good science. Lives are at stake when subtle statistical signals of benefit and risk are sought in noisy, messy trial data. We hope that the structures of science really are in a state of flux, and still changing. 
